# The FDA has proposed excluding the active ingredients in wildly popular obesity and diabetes drugs from a list of substances that can be used for making certain compounded versions.

*biotech · news · 2026-04-30 · STAT*

## Key points

- The FDA proposed excluding semaglutide and tirzepatide from allowed substances for large-scale compounding.
- The FDA found no clinical need for 503B facilities to compound semaglutide or tirzepatide drugs.
- 503B compounders can no longer legally market compounded versions of Wegovy, Ozempic, Moujaro, or Zepbound.
- This move favors Novo Nordisk and Eli Lilly by restricting alternative supply from large compounders.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/pharmalot/2026/04/30/fda-weight-loss-drugs-new-rule-would-end-glp-1-compound-pharmacy/)

---

Canonical: https://newsio.io/n/14d99046-2506-46fc-954c-27a5da44b258/the-fda-has-proposed-excluding-the-active-ingredients-in-wildly-popular-obesity
Summarized by Newsio from STAT. https://newsio.io/how-it-works